Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back PainSeeking Alpha · 6 days ago
Mesoblast (NASDAQ:MESO) Stock Price Breaks Below 50 Day Moving Average – Should You Sell?Defense World · Oct 13, 2026
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil ProductGlobeNewsWire · Sep 24, 2026
Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head ContrastDefense World · Sep 18, 2026
Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average – Time to Sell?Defense World · Sep 4, 2026
Mesoblast Limited (MESO) Q4 2026 Earnings Call TranscriptSeeking Alpha · Aug 27, 2026Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 26, 2026 | -$0.11 | -$0.13 | Miss |
| Apr 30, 2026 | -$0.08 | -$0.07 | Beat |
| Feb 26, 2026 | -$0.24 | -$0.31 | Miss |
| Aug 28, 2025 | -$0.20 | -$0.32 | Miss |
| Jul 29, 2025 | -$0.37 | -$0.43 | Miss |
| Apr 30, 2025 | -$0.35 | -$0.21 | Beat |